AP576A - Salts of an anti-migraine indole derivatives. - Google Patents

Salts of an anti-migraine indole derivatives. Download PDF

Info

Publication number
AP576A
AP576A APAP/P/1995/000754A AP9500754A AP576A AP 576 A AP576 A AP 576A AP 9500754 A AP9500754 A AP 9500754A AP 576 A AP576 A AP 576A
Authority
AP
ARIPO
Prior art keywords
compound
formula
suitable solvent
pharmaceutical composition
treatment
Prior art date
Application number
APAP/P/1995/000754A
Other languages
English (en)
Other versions
AP9500754A0 (en
Inventor
Valerie Denise Harding
Ross James Macrae
Roland James Ogilvie
Original Assignee
Pfizer Ireland Pharmaceuticals
Pfizer Res & Development Company N V /S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10760474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals, Pfizer Res & Development Company N V /S A filed Critical Pfizer Ireland Pharmaceuticals
Publication of AP9500754A0 publication Critical patent/AP9500754A0/xx
Application granted granted Critical
Publication of AP576A publication Critical patent/AP576A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
APAP/P/1995/000754A 1994-08-27 1995-07-27 Salts of an anti-migraine indole derivatives. AP576A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9417310A GB9417310D0 (en) 1994-08-27 1994-08-27 Therapeutic agents

Publications (2)

Publication Number Publication Date
AP9500754A0 AP9500754A0 (en) 1995-07-31
AP576A true AP576A (en) 1997-03-20

Family

ID=10760474

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1995/000754A AP576A (en) 1994-08-27 1995-07-27 Salts of an anti-migraine indole derivatives.

Country Status (45)

Country Link
US (2) US6110940A (fr)
EP (1) EP0776323B1 (fr)
JP (1) JP2904588B2 (fr)
KR (1) KR100228952B1 (fr)
CN (1) CN1066727C (fr)
AP (1) AP576A (fr)
AT (1) ATE163182T1 (fr)
AU (1) AU691005B2 (fr)
BG (1) BG61840B1 (fr)
BR (1) BRPI9503812B1 (fr)
CA (1) CA2198599C (fr)
CO (1) CO4410334A1 (fr)
CZ (1) CZ287693B6 (fr)
DE (1) DE69501620T2 (fr)
DK (1) DK0776323T3 (fr)
DZ (1) DZ1923A1 (fr)
EG (1) EG23822A (fr)
ES (1) ES2112650T3 (fr)
FI (1) FI113768B (fr)
GB (1) GB9417310D0 (fr)
GR (1) GR3026475T3 (fr)
HR (1) HRP950460B1 (fr)
HU (1) HU227822B1 (fr)
IL (1) IL115013A (fr)
IS (1) IS1850B (fr)
LV (1) LV11800B (fr)
MA (1) MA23650A1 (fr)
MX (1) MX9701538A (fr)
MY (1) MY113733A (fr)
NO (1) NO311297B1 (fr)
NZ (1) NZ288210A (fr)
OA (1) OA10600A (fr)
PE (1) PE41596A1 (fr)
PL (1) PL180867B1 (fr)
RO (1) RO116400B1 (fr)
RU (1) RU2159241C2 (fr)
SA (1) SA95160156B1 (fr)
SI (1) SI9520091B (fr)
SK (1) SK282922B6 (fr)
TN (1) TNSN95092A1 (fr)
TR (1) TR199501061A2 (fr)
UA (1) UA45980C2 (fr)
WO (1) WO1996006842A1 (fr)
YU (1) YU49287B (fr)
ZA (1) ZA957142B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
JP3350061B2 (ja) * 1997-07-03 2002-11-25 ファイザー・インク エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物
GB9714081D0 (en) * 1997-07-03 1997-09-10 Pfizer Ltd Pharmaceutical compositions
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US20030166704A1 (en) * 2000-12-20 2003-09-04 Pfizer Inc. New process
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
BRPI0409127A (pt) 2003-04-11 2006-03-28 Pfizer combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
RU2313340C1 (ru) * 2006-02-20 2007-12-27 Дмитрий Владимирович Зимин Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
CA2666149A1 (fr) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Indoles substitues
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP1956018A1 (fr) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé de préparation d'un dérivé du benzimidazole
EP2093225A1 (fr) 2007-05-01 2009-08-26 Plus Chemicals B.V. Procédé de préparation de la forme ß de l'hydrobromide d'élétriptan crystallin
WO2008150500A1 (fr) * 2007-05-29 2008-12-11 Plus Chemicals, S.A. Procédé pour préparer du 5-bromo-3-[(r)-1-méthyl-pyrrolidin-2-yl-méthyl]-1h-indole
WO2009077858A2 (fr) * 2007-12-17 2009-06-25 Actavis Group Ptc Ehf Sel semioxalate innovant de l'élétriptan
WO2009142771A2 (fr) * 2008-05-22 2009-11-26 Plus Chemicals, S.A. Sels de (r)-5-(2-phénylsulfonyléthényl)-3-(n-méthylpyrrolidin-2-ylméthyl)-1h-indole, de 5-bromo-3-[(r)-1-méthyl-pyrrolidin-2-ylméthyl]-1h-indole et d’élétryptan
CA2934988A1 (fr) * 2008-08-07 2010-02-11 Valeant International Bermuda Polymorphes de bromhydrate de bupropion
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (fr) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Nouveau polymorphe de bromhydrate d'életriptan et son procédé de fabrication
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (fr) 2009-06-25 2011-01-13 Matrix Laboratories Ltd Procédé amélioré d'élaboration d'élétriptane et son sel correspondant
WO2011089614A1 (fr) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited Procédé de préparation de bromhydrate d'élétriptan ayant une forme α
WO2014063752A1 (fr) 2012-10-26 2014-05-01 Synthon Bv Procédé de production de la forme cristalline alpha du bromhydrure d'élétriptan
WO2017125351A1 (fr) 2016-01-21 2017-07-27 Laboratorios Lesvi Sl Procédé de préparation de ((r)-3-[(-1-méthylpyrrolidin-2-yl)méthyl]-5-(2-phénylsulfonyléthyl)-1h-indole

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (fr) * 1990-10-15 1992-04-30 Pfizer Inc. Derives d'indole

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CA2124206C (fr) * 1991-11-25 2001-02-27 John Eugene Macor Derives indole
GB9201038D0 (en) * 1992-01-16 1992-03-11 Glaxo Group Ltd Chemical compounds
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
TW288010B (fr) * 1992-03-05 1996-10-11 Pfizer
RU2101283C1 (ru) * 1992-04-07 1998-01-10 Пфайзер Инк. Производные индола или их фармацевтически приемлемые соли
AU670270B2 (en) * 1992-04-10 1996-07-11 Pfizer Inc. Acylaminoindole derivatives as 5-HT1 agonists
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
HUT73807A (en) * 1993-04-22 1996-09-30 Pfizer Res & Dev 5-ht1-like indole derivatives and pharmaceutical compositions containing them
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
CN1129933A (zh) * 1993-08-31 1996-08-28 辉瑞大药厂 5-芳基吲哚衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (fr) * 1990-10-15 1992-04-30 Pfizer Inc. Derives d'indole

Also Published As

Publication number Publication date
IS4401A (is) 1996-12-19
FI113768B (fi) 2004-06-15
MX9701538A (es) 1997-05-31
YU56995A (sh) 1998-07-10
EP0776323B1 (fr) 1998-02-11
MA23650A1 (fr) 1996-04-01
UA45980C2 (uk) 2002-05-15
EP0776323A1 (fr) 1997-06-04
NO311297B1 (no) 2001-11-12
DZ1923A1 (fr) 2002-02-17
EG23822A (en) 2007-09-19
SK282922B6 (sk) 2003-01-09
ZA957142B (en) 1997-02-25
AU691005B2 (en) 1998-05-07
CN1155886A (zh) 1997-07-30
BG101250A (en) 1997-09-30
GB9417310D0 (en) 1994-10-19
PL318319A1 (en) 1997-06-09
CN1066727C (zh) 2001-06-06
DE69501620T2 (de) 1998-07-02
WO1996006842A1 (fr) 1996-03-07
YU49287B (sh) 2005-03-15
SA95160156B1 (ar) 2005-05-30
SK24897A3 (en) 1998-08-05
PE41596A1 (es) 1996-10-12
HRP950460A2 (en) 1997-08-31
CA2198599C (fr) 2000-06-06
NZ288210A (en) 1998-01-26
RO116400B1 (ro) 2001-01-30
MY113733A (en) 2002-05-31
SI9520091A (sl) 1998-02-28
JPH09512283A (ja) 1997-12-09
NO970861D0 (no) 1997-02-26
FI970800A0 (fi) 1997-02-26
SI9520091B (sl) 2004-10-31
KR100228952B1 (ko) 1999-11-01
BRPI9503812B1 (pt) 2017-04-18
CZ56397A3 (cs) 1998-05-13
FI970800L (fi) 1997-02-26
HRP950460B1 (en) 2000-02-29
OA10600A (en) 2000-04-06
GR3026475T3 (en) 1998-06-30
LV11800A (lv) 1997-06-20
NO970861L (no) 1997-02-26
CZ287693B6 (en) 2001-01-17
IL115013A (en) 2000-11-21
BG61840B1 (bg) 1998-07-31
IL115013A0 (en) 1995-12-08
LV11800B (en) 1997-10-20
KR970705557A (ko) 1997-10-09
DE69501620D1 (de) 1998-03-19
BR9503812A (pt) 1996-04-16
JP2904588B2 (ja) 1999-06-14
AU2735295A (en) 1996-03-22
HU227822B1 (en) 2012-03-28
AP9500754A0 (en) 1995-07-31
CO4410334A1 (es) 1997-01-09
IS1850B (is) 2003-02-07
HUT77310A (hu) 1998-03-30
US6110940A (en) 2000-08-29
ES2112650T3 (es) 1998-04-01
PL180867B1 (pl) 2001-04-30
TR199501061A2 (tr) 1996-06-21
DK0776323T3 (da) 1998-03-30
RU2159241C2 (ru) 2000-11-20
CA2198599A1 (fr) 1996-03-07
ATE163182T1 (de) 1998-02-15
TNSN95092A1 (fr) 1996-02-06
US6380226B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
AP576A (en) Salts of an anti-migraine indole derivatives.
US20100273808A1 (en) Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
EP2593091A1 (fr) Compositions pharmaceutiques modulatrices de c-met
CA2379572C (fr) Sel polymorphe
RU2349585C2 (ru) Стабильные модификации гидромалеата тегасерода
BG104940A (bg) Пароксетин аскорбат